Weight-Loss Shot Stuns Sleep Apnea

Healthcare worker drawing blue liquid from vial with syringe — Photo: New Africa / Shutterstock

A once-weekly injection built to fight obesity just showed it can also quiet arthritic knees and stop people from gasping for air at night.

Quick Take

Eli Lilly’s experimental drug retatrutide sharply reduced knee osteoarthritis pain and sleep apnea severity in a large Phase 3 trial.
Patients on the drug saw knee pain scores drop by up to 3.6 points and breathing interruptions fall by more than 34 events per hour.
The trial, called TRIUMPH-1, enrolled thousands of patients and tested the drug alongside weight loss, not as a separate treatment.
Retatrutide is still unapproved, and it joins a growing list of obesity drugs showing benefits beyond the scale.

Clinical Trial Results Show Major Pain and Breathing Improvements

Lilly’s TRIUMPH-1 trial tracked how retatrutide affected people with obesity who also suffered from knee osteoarthritis or moderate-to-severe obstructive sleep apnea. After 80 weeks, patients taking the 9 or 12 milligram doses saw their knee pain scores fall by 3.5 to 3.6 points on a standard pain scale, compared to just 1.9 points for those on placebo. Both results were statistically significant.

The sleep apnea numbers were even more striking. Patients on retatrutide cut their breathing interruptions, measured by the apnea-hypopnea index, by 31.7 to 34.3 events per hour. Placebo patients improved by just 9.9 events. Lilly says both the pain and breathing changes blew past the thresholds doctors consider medically meaningful, not just statistically notable.

How Retatrutide Works and Why Weight Loss Matters

Retatrutide belongs to a class of drugs that mimic gut hormones to curb appetite and boost metabolism, the same family that includes Ozempic and Zepbound. Lilly reports weight loss tied to the drug reached as high as 73 percent reduction in reported pain scores and 60 percent reduction in breathing events from baseline levels. Extra body weight strains joints and narrows airways during sleep, so shedding pounds plausibly drives much of the improvement seen in both conditions.

The TRIUMPH program behind these findings is no small study. Lilly describes it as four global trials launched in 2023, enrolling more than 5,800 participants, with specific groups set aside to study knee osteoarthritis and sleep apnea outcomes. That scale gives the results weight that smaller, early-stage studies typically cannot match.

Part of a Broader Shift in Treating Obesity-Linked Disease

Retatrutide is not working alone in this space. Tirzepatide, sold as Zepbound, already showed in the SURMOUNT-OSA trials that it can cut sleep apnea breathing interruptions by 20 to 24 events per hour, depending on whether patients also used a breathing machine at night. Semaglutide, the active ingredient in Wegovy, has separately shown it can ease knee pain and improve physical function in osteoarthritis patients, according to a review published in Nature Medicine.

Doctors and researchers increasingly treat obesity itself as a root cause of chronic disease rather than just a risk factor sitting alongside it. That shift matters for patients who have spent years managing joint pain or sleep troubles as separate problems from their weight, when the same injection might now address several issues at once.

What Comes Next Before Patients Can Access the Drug

Retatrutide remains investigational and is not approved for use in any country. That means the knee and sleep apnea results, however strong, still need to clear regulatory review before doctors can prescribe the drug for those specific conditions. Lilly has not said when it expects to file for approval covering these uses.

For now, the data gives patients and doctors a clearer picture of what obesity drugs might accomplish beyond weight loss alone. Millions of Americans live with both extra weight and the joint pain or sleep disruption that often comes with it. A single treatment addressing all three would mark a real shift in how chronic disease gets managed, not just how many pounds come off the scale.